Literature DB >> 10653384

Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.

B Hausen1, T Ikonen, N Briffa, G J Berry, U Christians, R C Robbins, L Hook, N Serkova, L Z Benet, W Schuler, R E Morris.   

Abstract

BACKGROUND: We studied the efficacy and tolerability of combined immunosuppressive therapy with cyclosporine A microemulsion (Neoral) plus the macrolide SDZ RAD 40-0 (2-hydroxyethyl) rapamycin (RAD) in a stringent cynomolgus monkey lung graft model in comparison with cyclosporine or SDZ RAD monotherapy.
METHODS: Thirty-nine cynomolgus monkeys received mixed lymphocyte reaction (MLR) mismatched unilateral lung transplants. Immunosuppressants were administered orally as single daily doses. The observation period was 28 days and follow-up included serial trough blood drug concentrations measured by high performance liquid chromatography/mass spectrometry, blood analyses, chest radiographs, open lung biopsies, as well as tissue drug concentrations and graft histology at necropsy.
RESULTS: Graft biopsies in monkeys treated with vehicle (n=4), Neoral (day 1-7: 150 mg/kg/day; day 8-28: 100 mg/kg/day; n=6; mean +/- SE trough level (MTL): 292+/-17 ng/ml) or SDZ RAD monotherapy (1.5 mg/kg/day; n=6; MTL: 15+/-1 ng/ml) showed severe rejection. Coadministration in two transplant monkeys of Neoral (150/100 mg/kg/day) and SDZ RAD (1.5 mg/kg/day) caused their early death. In both animals, SDZ RAD blood levels were more than 5-fold higher than under monotherapy (MTL: 82+/-18 ng/ml). Simultaneous administration (n=6) of Neoral (150/100 mg/kg/day; MTL: 217+/-16 ng/ml) and SDZ RAD (0.3 mg/kg/day; MTL: 24+/-2 ng/ml) improved graft outcome (mild rejection). Side effects included renal failure (n=2) and seizures (n=1). Three monkeys survived to day 28. In this group the MTL for cyclosporin was 143+/-13 and for RAD 38+/-3. Staggered treatment completely prevented rejection in four of six grafts. However, five of six monkeys had moderate to severe diarrhea. In a concentration-controlled trial of simultaneously administered Neoral and SDZ RAD in transplant monkeys (target SDZ RAD MTL: 20-40 ng/ml; cyclosporine MTL: 100-200 ng/ml) all six monkeys survived with improved drug tolerability and an average biopsy score of mild rejection.
CONCLUSION: Combination of orally administered SDZ RAD and Neoral showed excellent immunosuppressive efficacy in a stringent lung transplant model. The drug interaction and the narrow therapeutic index of this drug combination required careful dose adjustments to optimize tolerability and efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10653384     DOI: 10.1097/00007890-200001150-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Primate models in organ transplantation.

Authors:  Douglas J Anderson; Allan D Kirk
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

2.  Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain.

Authors:  N Serkova; W Jacobsen; C U Niemann; L Litt; L Z Benet; D Leibfritz; U Christians
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 3.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Long-term lung transplantation in nonhuman primates.

Authors:  A Aoyama; M Tonsho; C Y Ng; S Lee; T Millington; O Nadazdin; J C Wain; A B Cosimi; D H Sachs; R N Smith; R B Colvin; T Kawai; J C Madsen; G Benichou; J S Allan
Journal:  Am J Transplant       Date:  2015-03-13       Impact factor: 8.086

5.  Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats.

Authors:  Michael Deters; Gabriele Kirchner; Therese Koal; Klaus Resch; Volkhard Kaever
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 6.  Clinical pharmacokinetics of everolimus.

Authors:  Gabriele I Kirchner; Ivo Meier-Wiedenbach; Michael P Manns
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.

Authors:  Robert Laplanche; Guy M L Meno-Tetang; Ryosei Kawai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-03-13       Impact factor: 2.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.